BioCentury
ARTICLE | Clinical News

Array reports updated Phase III OS data for triple combo mCRC therapy

February 8, 2019 5:34 AM UTC

Array BioPharma Inc. (NASDAQ:ARRY) reported updated data from the safety lead-in portion of the Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a median overall survival of 15.3 months among 29 evaluable BRAF V600E-mutant metastatic colorectal cancer (mCRC) patients who progressed after one or two prior lines of therapy. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

The combo also led to an updated median progression-free survival of eight months and an updated confirmed overall response rate (ORR) of 48%, including three complete responses and 11 partial responses plus 13 cases of stable disease...